Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Corcept Therapeutics develops medications that modulate cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core products include Korlym and relacorilant for hypercortisolism, with ongoing trials for cancer, liver disease, ALS, and metabolic conditions. The company leverages proprietary cortisol modulators, patents, and strategic collaborations to address unmet medical needs in hormone regulation and cancer therapy.
This description was generated via AI from an annual report. Updated about 1 year ago.